View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 28, 2022

Harvard Wyss Institute licenses biosensor technology to StataDx

The eRapid electrochemical sensing platform has been designed for detecting a wide range of biomarkers.

The Wyss Institute for Biologically Inspired Engineering at Harvard University has licensed its eRapid electrochemical biosensor technology to US-based start-up StataDx.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Coordinated by Harvard’s Office of Technology Development (OTD), the licence provides the start-up with exclusive and worldwide access to the technology in the renal diseases, neurological and cardiovascular fields.

The affinity-based, multiplexed, electrochemical sensing platform has been designed for detecting a wide range of biomarkers simultaneously from a single blood drop or complex biological fluids with high sensitivity and selectivity.

eRapid includes a new antifouling nanocomposite coating, which has probes attached that are specific to the target biomarker.

This coating allows the electrochemical electrodes to withstand the attack of biofouling molecules in various biofluids and maintain the sensing capabilities while also reducing any electrochemical background signals.

Wyss Institute researchers Sanjay Sharma Timilsina and Nolan Durr, who were involved in the development of eRapid, will join StataDx’s team.

The team’s focus will be on developing diagnostic tests for use in near-patient settings, such as physician offices, pharmacies and at-home settings.

StataDX CEO and co-founder Sidhant Jena said: “While there are many at-home tests for viral diseases such as Covid-19 available today, nothing yet exists for patients with complex chronic diseases, such as multiple sclerosis, heart failure or chronic kidney disease, that need periodic measurements of multiple biomarkers.

“The approach enabled by eRapid addresses underlying limitations of electrochemical biosensing in an elegant way, which may overcome the challenge faced by so many promising diagnostic technologies – the successful transfer to manufacturing at scale.

“Our decision to pursue neurology first stems from the significant healthcare burden of an ageing population and the complete absence of a fingerprick blood test for the brain.”

Last May, the Wyss Institute licensed its sample collection swab and high-throughput automation technologies to start-up company Rhinostics.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network